摘要
目的 :探讨 CED方案加 CD3 AK细胞治疗晚期非小细胞肺癌 (NSCL C)的近期疗效。方法 :对 2 3例晚期 NSCL C采用 CEC方案加 CD3 AK进行治疗 (A组 ) ;同时对 17例相同患者单纯进行 CED方案化疗 (B组 )。结果 :1A组临床有效率为 78.2 6 % (18/2 3) ,B组临床有效率为 35 .2 9% (6 /17) ,两组相比有显著差异 (P =0 .0 15 ) ;2 A组 1年生存率为 82 .6 1%(19/2 3) ,B组为 47.0 6 % (8/17) (P =0 .0 42 ) ;3化疗反应 A组较 B组轻 ,但两组相比无显著差异 (P >0 .0 5 )。结论 :CD3 AK细胞与 CED化疗协同治疗晚期非小细胞肺癌可以明显提高效果。
Objective:To evaluate the therapeutic results in treatment of advanced primary non small cell lung cancer (NSCLC) with CED chemotherapy and CD 3AK cells Methods:23 patients of NSCLC were treated with CED chemotherapy and CD 3AK cells (group A) and 17 patients of those were treated with CED chemotherapy alone (group B) Results:① The rates of remission were 78 26% in Group A and 35 29% in Group B (p=0,015);②The one year survival rates were 82 61%in Group A and were 47 06%in Group B There were significant differences between them (P=0 042) ③The side effects of chemotherapy in Group B was stronger than that of Group A But there was no significant difference between them (P>0 05) Conclusion:Treatment with combination of CD 3AK and CED chemotherapy proved safe and effective for NSCLC,But the combination could not reduce the side effects of chemotherapy
出处
《广西医科大学学报》
CAS
2001年第5期617-618,共2页
Journal of Guangxi Medical University
